🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Lupin Limited recently announced the US Food and Drug Administration (FDA) approval for the company’s Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Gel, 0.38%. hubs.li/Q03vCKJQ0

Beacon Therapeutics has exercised its option agreement to license Abeona Therapeutics’ patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases that result in blindness. hubs.li/Q03vCMT-0

The risk of age-related macular degeneration (AMD) was found to increase as a result of exposure to the urinary dialkyl phosphate (DAP) metabolites in organophosphorus pesticides (OPPs) hubs.li/Q03vCLHW0

Bausch + Lomb has announced the launch of a new campaign in light of new survey data concerning patient awareness and education about dry eye. hubs.li/Q03vCQ-z0

Biocon Biologics received a Notice of Compliance (NOC) from Health Canada for Yesafili (aflibercept 2 mg), a biosimilar to Eylea, in vial and prefilled syringe presentations at 2 mg/0.05 mL. hubs.li/Q03vCSSY0

As part of the celebration of Ophthalmology Times’ 50th anniversary, Inder Paul Singh, MD, gave his perspectives on some of the most significant advancements in glaucoma care over the past 5 decades, along with a look at future innovations hubs.li/Q03vCKCX0

ModMed conducted a new survey on 2000 US patients on their comfort with AI use in medical practices that showed that patients still feel uneasy about AI use in diagnosis or creating a treatment plan, with 55% of respondents saying they were uncomfortable hubs.li/Q03vCSLD0

The risk of age-related macular degeneration (AMD) was found to increase as a result of exposure to the urinary dialkyl phosphate (DAP) metabolites in organophosphorus pesticides (OPPs) hubs.li/Q03vCWK30

At the 2025 International SPECTRALIS Symposium—And Beyond (ISS), Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in living subjects. hubs.li/Q03vCRVB0

Alcon is continuing its trend of acquisitions in 2025 with the recent announcement that the company will acquire LumiThera, Inc. and its photobiomodulation (PBM) device for the treatment of early and intermediate dry age-related macular degeneration (AMD) hubs.li/Q03w3xng0

Two phase 2a clinical trials showed positive results for the PER-001 intravitreal implant as the first disease-modifying treatment for glaucoma and diabetic retinopathy (DR), according to a press release issued by Perfuse Therapeutics. hubs.li/Q03w4Kcy0

4D Molecular Therapeutics has announced it is accelerating its 4D-150 4FRONT phase 3 program in wet age-related macular degeneration (wet AMD) and will lay off approximately 25% of staff. hubs.li/Q03w3y280

LENZ Therapeutics and Laboratoires Théa have announced a license and commercialization agreement for Théa to register and commercialize LNZ100 for the treatment of presbyopia in Canada. hubs.li/Q03wdnl70

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study (NCT06962839). THULITE will evaluate the efficacy, safety, and tolerability of BI 1815368, an oral medication for the treatment of diabetic macular edema (DME). hubs.li/Q03wdkJ30

Beacon Therapeutics has completed enrollment in its registrational phase 2/3 VISTA trial evaluating laru-zova for the treatment of X-linked retinitis pigmentosa (XLRP). hubs.li/Q03wdn8V0

First-time results of the phase 2 VERONA (NCT06099184) trial of the vorolanib intravitreal insert known as EYP-1901 (Duravyu; EyePoint) for diabetic macular edema (DME) were presented at the Retina World Congress 2025 in Fort Lauderdale, Florida. hubs.li/Q03wdp0m0

A class 2 medicines recall of Zaditen 0.25 mg/ml, eye drops, solution, has been issued in the United Kingdom after Laboratoires Théa notified the MHRA of an event during manufacturing that may increase the risk of microbial contamination in the product hubs.li/Q03wv3W30

PulseSight Technologies recently announced the successful dosing of the first patient in the phase I clinical trial PST-611-CT1, investigating the safety and tolerability of PST-611 for the treatment of AMD and geographic atrophy (GA). hubs.li/Q03wtYYY0

Belite Bio, Inc. has completed enrollment in the PHOENIX trial. The PHOENIX study is a 24-month, randomized, double-masked, placebo-controlled, multicenter, pivotal Phase 3 trial for this oral medication. hubs.li/Q03wFX7w0

As Ophthalmology Times celebrates its 50th anniversary, ophthalmologists shared their insights on the profession’s evolution, celebrating technological advances and paradigm shifts that continue to define modern eye care. hubs.ly/Q03wFY770